Literature DB >> 31600363

Error in Author's Name.

.   

Abstract

Entities:  

Year:  2019        PMID: 31600363      PMCID: PMC6802047          DOI: 10.1001/jamaoncol.2019.4781

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  1 in total

1.  Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial.

Authors:  Ghassan K Abou-Alfa; Qian Shi; Jennifer J Knox; Andreas Kaubisch; Donna Niedzwiecki; James Posey; Benjamin R Tan; Petr Kavan; Rakesh Goel; Philip E Lammers; Tanios S Bekaii-Saab; Vincent C Tam; Lakshmi Rajdev; Robin K Kelley; Imane El Dika; Tyler Zemla; Ryan I Potaracke; Jennifer Balletti; Anthony B El-Khoueiry; James J Harding; Jennifer M Suga; Lawrence H Schwartz; Richard M Goldberg; Monica M Bertagnolli; Jeffrey Meyerhardt; Eileen M O'Reilly; Alan P Venook
Journal:  JAMA Oncol       Date:  2019-11-01       Impact factor: 31.777

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.